EMA – CAT quarterly highlights and approved ATMPs – November 2023-January 2024
- During its plenary meeting of December 2023, CAT adopted a positive draft opinion for Casgevy (exagamglogene autotemcel) for the treatment of transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD). Based on the assessment of the CAT, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a Conditional marketing authorisation for the medicinal product Casgevy.
- During its plenary meeting of January 2024, CAT adopted an extension of indication for Abecma to include the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies.
More information in the CAT quarterly highlights and approved ATMPs document and more CAT report on the EMA Website.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (22 juillet 2024). EMA – CAT quarterly highlights and approved ATMPs – November 2023-January 2024. ELSIBI. Consulté le 12 octobre 2026 à l’adresse https://doi.org/10.58079/122ng
